Mobilization by Plerixafor of Haematopoietic Stem Cells in Children (MEP1)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier:
NCT01225419
First received: October 5, 2010
Last updated: July 4, 2014
Last verified: July 2014

October 5, 2010
July 4, 2014
September 2010
May 2011   (final data collection date for primary outcome measure)
Percentage of the children to whom 5.106 cells CD34 + / kg can be collected in 2 masses blood treated (one cytapheresis). [ Time Frame: between H4 and H9 at day 0 ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01225419 on ClinicalTrials.gov Archive Site
  • Describe the kinetics of mobilization of the hematopoietic progenitor at the child in situation of hematopoietic stable state after a subcutaneous injection of plerixafor [ Time Frame: between the injection and the apheresis at day 0 ] [ Designated as safety issue: Yes ]
  • Describe the pharmacokinetics of the plerixafor at the child [ Time Frame: between the injection and the apheresis at day 0 ] [ Designated as safety issue: Yes ]
  • Describe the side effects [ Time Frame: day 0 to day 3 ] [ Designated as safety issue: Yes ]
  • Describe the capacity of hematopoietic reconstruction of taken cells after mobilization by plerixafor only [ Time Frame: during the 30 following days ] [ Designated as safety issue: Yes ]
  • the toxicity of the plerixafor at the child. [ Time Frame: day 0 to day 3 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Mobilization by Plerixafor of Haematopoietic Stem Cells in Children
Mobilization by Plerixafor of Haematopoietic Stem Cells in Children

This is a prospective Phase II, monocentre study.

The extensive chemotherapy followed of hematopoietic stem cells reinjection (HSC) is one therapeutic option which the profit is well demonstrated in the treatment of children's solid tumors. It's one of the "standard" treatment of the following tumors: neuroblastoma, metastatic medulloblastoma, Ewing sarcoma, lymphoma in relapse; and because of the big chemosensibility of paediatric cancers, stays an important therapeutic option in the rhabdomyosarcoma in relapse or metastatic, nephroblastoma, etc. The stem cells can be taken in the blood by cytapheresis after mobilization with pharmacologic molecules. At present, the reference of the mobilization treatment is the G-CSF (Granulocyte colony-stimulating factor) in monotherapy during 4 to 6 days. His inconveniences are: lasted of the treatment (4 to 6 days), reproduction of the injections (1 to 2 subcutaneous injections daily), day variability of the peak of mobilization, this hematopoietic stimulation imposes to delay the chemotherapy. The plerixafor activates a massive and fast mobilization of the HSC ( hematopoietic stem cells)(between 6 and 11 hours after the injection). Currently, it's indicated in association with the G-CSF ( Granulocyte colony-stimulating factor)in case of mobilization failure. However, his big flexibility of use could be of a big interest in monotherapy at the child. To date, there is in our knowledge no data on the use of this molecule at the child.

Schema of study: Subcutaneous injection of 240 µg/kg of Plerixafor (Mozobil ®, Genzyme) at 8 am the day of the cytapheresis. Determination of CD34+ cells circulating in h0 then every hour of h3 to h11. Taking by cytapheresis from the 5th hour of the injection if the rate of CD34+ is upper or equal in 10.106/l. If the rate of CD34+ in the blood does not reach 10.106/l after the first injection of plerixafor or if the first cytapheresis does not allow the collection of at least 5.106/kg CD34+ cells, the patient will be considered in failure and a conventional mobilization by G-CSF(Granulocyte colony-stimulating factor) will be programmed.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Children Cancer, Solid Tumor
Drug: Plerixafor, mozobil
Subcutaneous injection of 240 µg/kg of Plerixafor (Mozobil ®, Genzyme) at 8 am the day of the cytapheresis. Determination of CD34+ cells circulating in h0 then every hour of h3 to h11. Taking by cytapheresis from the 5th hour of the injection if the rate of CD34+ is upper or equal in 10.106/l. If the rate of CD34+ in the blood does not reach 10.106/l after the first injection of plerixafor or if the first cytapheresis does not allow the collection of at least 5.106/kg CD34+ cells, the patient will be considered in failure and a conventional mobilization by G-CSF will be programmed
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 0 to 18 years old
  • Solid malign tumor
  • Lansky score ≥ 70%
  • Indication of hematopoietic stem cell taking by cytapheresis for extensive chemotherapy followed by one or several reinjections of hematopoietic stem cells

Exclusion Criteria:

  • Administration of hematopoietic growth factors in 8 days preceding the injection of Plerixafor.
  • Contraindication in the cytapheresis or in the extensive chemotherapy.
  • Clinical or biological state dissuading the realization of the cytapheresis
  • Chemotherapy in 15 days preceding the injection of plerixafor or neutrophils < 1500/mm3
Both
up to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01225419
CHU-0082
Not Provided
University Hospital, Clermont-Ferrand
University Hospital, Clermont-Ferrand
Not Provided
Principal Investigator: Etienne MERLIN University Hospital, Clermont-Ferrand
University Hospital, Clermont-Ferrand
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP